In heart failure patients, SGLT2 inhibitors with low SGLT2/SGLT1 selectivity were more effective in reducing the risk of HHF compared to those with high selectivity, while this effect was not seen in non-heart failure patients. Here, SLC5A1 is linked to heart failure.